Figure 5From: Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay The effect of mevalonate pathway substrate replacement with mevalonate (Mev) at low, medium and high concentrations (5, 200, and 1537 μM respectively), geranylgeraniol (GG, 10 μM) and farnesyl diphosphate (FPP, 23 μM) on zoledronic acid (ZA) and fluvastatin (Fluva) activity in a recurrent ovarian cancer.Back to article page